RITCHEY RAYMOND A

Senior EVP RITCHEY RAYMOND A sold entire 36.3K BXP stake at $72.18 for $2.6M on 2025-12-01

RITCHEY RAYMOND A (Senior EVP) liquidated his complete BXP holding of 36,314 shares at $72.18 per share on 2025-12-01, totaling $2,621,133.63. The transaction represents a 100% reduction in his disclosed holdings at this company. At the cross-ticker level, RITCHEY's prior three open-market sells achieved a 66.67% well-timed rate over 90-day periods, indicating skill in selling before declines; however, at BXP specifically, his timing has been mixed—two of three prior sales there showed negative 90-day returns (-4.9% and -5.6%), while the third rose 8.2%. BXP's current fundamentals are stressed: the latest quarter shows a net loss of $121.7M against revenue of $871.5M, producing a P/E ratio of 797.22—an extreme denominator that reflects near-zero profitability. The stock trades at $71.75 today, 13.6% below its 52-week high and 0.43% below the sale price, suggesting the executive's execution occurred near recent peaks. The complete exit by a senior officer warrants attention given the weak profitability backdrop, though the cross-ticker track record provides some context for credibility in timing decisions.

Senior EVP RITCHEY sold 21.8K BXP shares at $74.25 on 2024-09-09 ($1.6M); eliminates common-stock tranche with strong prior timing record

RITCHEY sold 21.8K shares valued at $1,621,224.73, reducing his common-stock holdings to zero at $74.25 per share. This trade eliminates a specific batch of common equity; however, the filing FLAG indicates derivative securities held in Table II (not yet populated in our database) likely comprise the insider's real economic position. His cross-ticker track record shows a 100.00% well-timed rate across 2 prior sells (avg 90d return -5.2%), and at BXP specifically, both prior sales in 2023 were well-timed at the 90-day mark. The stock has since risen 24.3% over 90 days and trades at $74.51, near its 52-week high of $75.22. The trade occurs in a high-valuation environment (P/E 70.29) following recent 8.6% and 24.3% gains.